Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company's Immuno-Oncology Capabilities

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company's Immuno-Oncology Capabilities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New Data Demonstrate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier in Tailoring Treatment for Men With Prostate Cancer

New Data Demonstrate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data presented at the ASTRO 2021 Annual Meeting validate the prognostic ability of Veracyte's Decipher Prostate genomic classifier.

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at ASTRO 2021 reinforce the clinical utility of Veracyte's Decipher Prostate genomic classifier

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data published in the Journal of Urology demonstrate Veracyte's Decipher Bladder test can identify tumors most likely to respond to chemotherapy

New Publication Demonstrates Ability of Veracyte's Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Data to be presented at CHEST show Veracyte's Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis.

New Clinical Utility Data Confirm Veracyte's Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test's Ability to Improve Early Lung Cancer Assessment

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data to be presented at CHEST 2021 will showcase performance of Veracyte's genomic diagnostic tests in lung cancer and other lung diseases

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte's Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.

Is Veracyte Still a Buy After Its Recent Rally?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New NCCN Guidelines Recommend Use of Veracyte's Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men After Radical Prostatectomy

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Joshua Klopper as Medical Director, Endocrinology.

Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--South San Francisco-based Veracyte was named a Bay Area Top Workplace for the eighth consecutive year.

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year

AquaBounty Technologies

Catherine Wood (Trades, Portfolio) disclosed earlier this week her firm, ARK Investment Management, reduced two of its positions in July.

Cathie Wood Whittles Down 2 Positions in July

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte announced that the company has completed the acquisition of HalioDx.

Veracyte Completes Acquisition of HalioDx

Veracyte, Inc. (VCYT) CEO Marc Stapley on Q2 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Second Quarter 2021 Financial Results

Veracyte Announces Second Quarter 2021 Financial Results

Veracyte appointed Rebecca Chambers, who boasts a wealth of financial executive experience, to the position.

After Naming a New CFO, Is This Genetic Diagnostics Company a Buy?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Published data suggest Veracyte's Decipher Prostate Biopsy genomic classifier may help guide the use of active surveillance in prostate cancer

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021.

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Appointments of Rob Brainin and Bill Zondler to Executive Leadership Team, Supporting Global Expansion

Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte has appointed Dr. Bill Bulman and Dr. Kelly Marcom as the company's medical directors of Lung Cancer and Breast Cancer, respectively.

News for Veracyte Stock (VCYT)